| Literature DB >> 27515985 |
Neil Marlow1, Hannah Bower2, David Jones2, Peter Brocklehurst1, Sara Kenyon3, Katie Pike4, David Taylor5, Alison Salt6.
Abstract
BACKGROUND: Antibiotics used for women in spontaneous preterm labour without overt infection, in contrast to those with preterm rupture of membranes, are associated with altered functional outcomes in their children.Entities:
Keywords: Fetal Medicine; Neurodevelopment; Outcomes research; School Health
Mesh:
Substances:
Year: 2016 PMID: 27515985 PMCID: PMC5339554 DOI: 10.1136/archdischild-2015-310144
Source DB: PubMed Journal: Arch Dis Child Fetal Neonatal Ed ISSN: 1359-2998 Impact factor: 5.747
Summary statistics for contextual value added score and raw scores for English, maths and science by ORACLE treatment groups
| Erythromycin | No erythromycin | Co-amoxiclav | No co-amoxiclav | |
|---|---|---|---|---|
| 1512 | 1528 | 1523 | 1517 | |
| English (n) | 1275 | 1304 | 1303 | 1276 |
| Median (IQR) | 57 (45 to 67) | 58 (46 to 68) | 58 (46 to 68) | 57 (45 to 67) |
| Mathematics (n) | 1265 | 1314 | 1300 | 1279 |
| Median (IQR) | 64 (47 to 78) | 64 (47 to 79) | 64 (47 to 78) | 64 (47 to 79) |
| Science (n) | 798 | 814 | 812 | 800 |
| Median (IQR) | 59 (49 to 67) | 59 (50 to 67) | 60 (50 to 67) | 58 (49 to 67) |
| Contextual VA (n)* | 1090 | 1113 | 1105 | 1098 |
| Median (IQR) | 100.1 (98.6 to 101.5) | 100.1 (98.7 to 101.7) | 100.1 (98.6 to 101.5) | 100.2 (98.7 to 101.6) |
| Special needs (n)† | 1356 | 1387 | 1379 | 442/1364 |
| n (%) | 467 (34.4%) | 438 (31.6%) | 463 (33.6%) | (32.4%) |
| English (n) | 1328 | 1285 | 1275 | 1338 |
| Median (IQR) | 56 (45 to 66) | 56 (45 to 67) | 57 (45 to 68) | 56 (44 to 66) |
| Mathematics (n) | 1334 | 1287 | 1281 | 1340 |
| Median (IQR) | 62 (46 to 77) | 62 (47 to 77) | 63 (47 to 78) | 61 (46 to 77) |
| Science (n) | 813 | 787 | 776 | 824 |
| Median (IQR) | 59 (48 to 66) | 58 (48 to 66) | 59 (48 to 67) | 58 (48 to 66) |
| Contextual VA (n)* | 1138 | 1066 | 1065 | 1139 |
| Median (IQR) | 100.0 (98.5 to 101.6) | 100.0 (98.5 to 101.5) | 101.1 (98.7 to 101.6) | 100.0 (98.3 to 101.5) |
| Special needs (n)† | 1421 | 1345 | 1353 | 1413 |
| n (%) | 475 (33.4%) | 426 (31.7%) | 427 (31.6%) | 474 (33.5%) |
Scores are the number of marks achieved.
*Contextual value added (VA) scores are expressed as a per cent improvement compared with previous assessments; for further definitions, see http://www.education.gov.uk/schools/performance/archive/schools_10/s3.shtml; accessed 30 March 2016.
†Special need categories: school action, school action plus (for 2004–2006 also includes educational statements and statutory assessment); for definitions, see, https://http://www.gov.uk/children-with-special-educational-needs/support-before-september-2014; accessed 30 March 2016.
Educational attainment lower than level 4* in English, mathematics and science at Key Stage 2 by ORACLE treatment groups
| Erythromycin | No erythromycin | Co-amoxiclav | No co-amoxiclav | |
|---|---|---|---|---|
| 1512 | 1528 | 1523 | 1517 | |
| English (n) | ||||
| <Level 4 (%) | 350 (25.6) | 342 (24.6) | 326 (23.5) | 366 (26.7) |
| OR (95% CI)† | 1.05 (0.89 to 1.26) | 0.85 (0.71 to 1.01) | ||
| Mathematics (n) | ||||
| <Level 4 (%) | 377 (27.7) | 364 (26.1) | 366 (26.4) | 375 (27.4) |
| OR (95% CI) | 1.08 (0.91 to 1.29) | 0.95 (0.80 to 1.13) | ||
| Science (n) | ||||
| <Level 4 (%) | 126 (15.1) | 129 (15.3) | 119 (14.1) | 136 (16.3) |
| OR (95% CI) | 0.98 (0.75 to 1.30) | 0.84 (0.64 to 1.11) | ||
| English (n) | ||||
| <Level 4 (%) | 352 (24.8) | 335 (24.8) | 321 (23.8) | 366 (25.8) |
| OR (95% CI) | 1.00 (0.84 to 1.19) | 0.90 (0.75 to 1.07) | ||
| Mathematics (n) | ||||
| <Level 4 (%) | 394 (27.7) | 360 (26.6) | 354 (26.1) | 400 (28.2) |
| OR (95% CI) | 1.06 (0.89 to 1.25) | 0.90 (0.76 to 1.07) | ||
| Science (n) | ||||
| <Level 4 (%) | 130 (15.4) | 117 (14.5) | 105 (13.2) | 142 (16.7) |
| OR (95% CI) | 1.07 (0.81 to 1.42) | 0.76 (0.57 to 1.01) | ||
*Level 4 is the minimum standard which children are expected to achieve.
†OR, Mantel–Haenszel ORs (95% CIs).
Erythromycin and co-amoxiclav HRs (95% CI) from the adjusted log-linear models for aggregate KS2 levels*
| PROM | SPL | |||
|---|---|---|---|---|
| Erythromycin | Co-amoxiclav | Erythromycin | Co-amoxiclav | |
| CC | 1.00 (0.96 to 1.05) | 1.03 (0.99 to 1.08) | 0.97 (0.92 to 1.03) | 1.01 (0.95 to 1.06) |
| <10% | 1.00 (0.96 to 1.03) | 1.02 (0.98 to 1.06) | 0.98 (0.95 to 1.02) | 1.01 (0.98 to 1.05) |
| CC | 0.98 (0.94 to 1.03) | 1.02 (0.97 to 1.07) | 0.99 (0.95 to 1.03) | 1.00 (0.96 to 1.05) |
| <10% | 0.98 (0.95 to 1.02) | 1.00 (0.96 to 1.04) | 0.99 (0.95 to 1.02) | 1.01 (0.97 to 1.05) |
| CC | 1.00 (0.95 to 1.05) | 1.02 (0.97 to 1.07) | 0.98 (0.93 to 1.04) | 1.01 (0.96 to 1.07) |
| <10% | 1.00 (0.95 to 1.04) | 1.01 (0.97 to 1.06) | 0.99 (0.94 to 1.04) | 1.02 (0.97 to 1.07) |
*See supplemental table 2 for details of covariates used (with <10% missing data).
<10%, <10% missing data; CC, complete case analysis; KS2, Key Stage 2; PROM, preterm rupture of membranes; SPL, spontaneous labour with intact membranes.
Erythromycin and co-amoxiclav estimates (95% CI) from the adjusted linear regression models for raw KS2 scores*
| PROM | SPL | |||
|---|---|---|---|---|
| Erythromycin | Co-amoxiclav | Erythromycin | Co-amoxiclav | |
| CC | −0.54 (−2.05 to 0.97) | 1.03 (−0.48 to 2.54) | 0.18 (−1.46 to 1.82) | 0.79 (−0.86 to 2.43) |
| <10% | −1.05 (−2.29 to 0.19) | −0.71 (−0.54 to 1.95) | −0.42 (−1.61 to 0.77) | 1.02 (−0.18 to 2.21) |
| CC | −1.10 (−3.18 to 0.97) | 0.82 (−1.26 to 2.89) | 0.18 (−2.07 to 2.42) | 1.46 (−0.80 to 3.71) |
| <10% | −0.74 (−2.40 to 0.92) | 0.09 (−1.57 to 1.74) | −0.07 (−1.67 to 1.54) | 1.55 (−0.05 to 3.15) |
| CC | 0.17 (−1.34 to 1.67) | 1.64 (0.14 to 3.15) | 1.47 (−0.40 to 3.34) | 1.31 (−0.57 to 3.18) |
| <10% | −0.07 (−1.34 to 1.19) | 0.94 (−0.33 to 2.20) | 0.37 (−0.91 to 1.65) | 0.96 (−0.32 to 2.24) |
*See supplemental table 3 for details of covariates used (with <10% missing data).
<10%, <10% missing data; CC, complete case analysis; KS2, Key Stage 2; PROM, preterm rupture of membranes; SPL, spontaneous labour with intact membranes.